The DrugSense project was aimed at commercializing the technology developed at the Sorek lab at the Weizmann Institute of Science, covered under U.S. provisional patent application 62/200,662. As planned, the expenses were used to cover the commercialization efforts as well as proof of concept experiments. These efforts resulted in the commercialization of the technology, which was eventually licensed by BiomX, a company developing novel therapeutics to alleviate microbiome-related diseases.
There is no overlap between the time that the PI dedicate to this project- DraugSense and the time that the PI dedicate to project PROKRNA.
